Journal
HISTOPATHOLOGY
Volume 66, Issue 5, Pages 747-751Publisher
WILEY-BLACKWELL
DOI: 10.1111/his.12501
Keywords
biomarker; hTERC; hTERT; hTR; in-situ hybridization; melanoma; rolling circle amplification; telomerase
Categories
Funding
- Health Research Fund of Central Denmark Region
Ask authors/readers for more resources
AimsTelomerase is reactivated in most cancers and there is accumulating evidence that this is a driver event in malignant melanoma (MM). Thus, our aim was to evaluate if in-situ hybridization (ISH)-based quantification of telomerase RNA (hTR) could be used to distinguish MM from naevi, and if there was a correlation with the Breslow thickness. Results and methodsWe created a tissue microarray (TMA) from formalin-fixed and paraffin-embedded tissue samples from 17 MM and 23 naevi, performed ISH targeting hTR, and quantified the signals. We found a more than eightfold greater number of hTR signals per nucleus in the MM samples compared to the naevi, and a positive correlation (P=0.0381) between the number of hTR signals per nucleus and the Breslow thickness. ConclusionQuantification of hTR ISH signals clearly distinguish MM from naevi (P<0.0001) and the number of signals per nucleus correlates with the Breslow thickness, suggesting that hTR might be a valuable biomarker in MM. Furthermore, as ISH-based detection requires the presence of both hTR and telomerase reverse transcriptase (hTERT), it might be an indicator of active telomerase and thus have future relevance as a predictive biomarker for anti-telomerase treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available